Case Studies & Whitepapers-End-to-end CDMO | Porton Pharma Solutions

CN
Newsroom


A Customer-centric, Innovative
and Reliable CDMO with Global Solutions

1-2 of 14 result
ENT-03 GRC Poster

Small MoleculesNov 09, 2024

ENT-03 GRC Poster

ENT-03 was predicted to be the mammalian equivalent of trodusquemine, based on knowledge of the bile acids produced in mammals, such as 7-HOCA. The individual C-25 isomers of ENT-03 were prepared and both detected in mouse brain. Trodusquemine and ENT-03 have both demonstrated dramatic effects in obesity and insulin resistance. (25S)-ENT-03 was selected for development for the treatment of diabetes and obesity.

Heterogeneous nucleation (HN)

Case Studies & WhitepapersNov 08, 2024

Co-processing Series: 4. Heterogeneous nucleation (HN)

In the context of crystallization, heterogeneous nucleation occurs when crystals form on a surface rather than spontaneously in the bulk solution, playing a crucial role in controlling crystal formation and growth. When applied to Co-processing, heterogeneous nucleation on the surface of excipients enhances material properties, allowing for greater control over critical attributes such as flowability, stability, and polymorphism.

Adsorption

Case Studies & WhitepapersOct 28, 2024

Co-processing Series: 3. Adsorption

This method involves the absorption of a dissolved drug into the pores of a carrier material, known as an adsorbent, with the drug remaining embedded in the porous media post-drying.

ASD Amorphous Solid Dispersions

Case Studies & WhitepapersOct 18, 2024

Co-processing Series: 2. ASD - How Co-Processing can replace Spray Drying

With spray drying, a prevalent method for producing amorphous solid dispersions (ASD), the process involves rapidly drying a solution with hot gas, resulting in high energy consumption and significant infrastructure and operational costs.

co-processing

Case Studies & WhitepapersOct 08, 2024

Co-processing Series: 1. What is co-processing and how is the industry embracing it?

Co-processing enhances the flow and density properties of active pharmaceutical ingredients (API) thus simplifying oral solid formulation. In some cases, co-processing can be used to generate Amorphous Solid Dispersion and offers more expeditious alternatives to traditional methods such as spray drying, nano-milling, or hot-melt extrusion.

Become part of Porton' s community to access personalized insights and resources.
Subscribe To Our Mailing List
Porton requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and our commitment to protecting your privacy, please review ourLegal Disclaimer terms and Porton Privacy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

This website provides information on products tailored for a diverse audience and may include product details or information that are not readily accessible or valid in your country. Please note that we do not accept any responsibility for accessing such information in a manner that may violate any legal processes, regulations, registrations, or usage guidelines in your country of origin.

Become part of Porton' s community to access personalized insights and resources.
Submit
By clicking “Submit” you agree to our Legal Disclaimer terms and conditions and the Porton Privacy and Cookies Policy.

ⓒ 2025 PORTON Legal Notices | Porton Privacy

US: (609) 860-1300
CN: (86) 23-8608-3200